Hereditary Pheochromocytoma and Paragangliomas Syndrome

Unraveling the Genetic Threads

Pheochromocytomas and paragangliomas, rare neuroendocrine tumors, can sometimes weave a complex genetic tale. A subset of these tumors is linked to a hereditary predisposition known as Hereditary Pheochromocytoma and Paragangliomas Syndrome (HPPS). At the heart of this syndrome are mutations in the succinate dehydrogenase (SDH) gene family, particularly involving the SDH B, C, and D subunits.

Genetic Intricacies

HPPS exhibits an autosomal dominant inheritance pattern for SDHA, SDHB, and SDHC mutations. In simpler terms, a mutation in just one copy of the gene can lead to the syndrome. However, the inheritance pattern takes an interesting turn for SDHD and SDHAF2 mutations, causing mutations only when inherited from affected fathers.

Beyond the SDH gene family, other players in this genetic orchestra include Myc associated protein X (MAX) and Transmembrane protein 127 (TEM127). The inheritance nuances further deepen, as MAX mutations result in tumors only when inherited from the father. Additionally, germline mutations in B and D subunits of SDH can be found in 10% of patients with sporadic pheochromocytoma (PCC).

Also Read: Acromegaly- Clinical Features, Diagnosis, Treatment

Pheochromocytomas: The Clinical Masquerade-Unmasking the Symptoms

Pheochromocytomas are notorious for their varied and episodic clinical presentation. The age of onset, equally distributed between genders, and the functional nature of these tumors contribute to their mystique.

Clinical Presentation

• Age of Onset: Typically in the 4th and 5th decades, with hereditary cases surfacing approximately 15 years earlier than sporadic ones.
• Gender Neutrality: Occurs equally in males and females.
• Functional Tumors: Secrete catecholamines, with distinct characteristics between adrenal PCC and paragangliomas.

The Classic Triad

1. Headache: The most common symptom.
2. Palpitation
3. Diaphoresis: Profuse sweating

Additional Symptoms

• Anxiety
• Flushing
• Tremulousness
• Pallor
• Weakness
• Weight loss
• Chest pain
• Shortness of breath

The Pathological Landscape

Unraveling the pathology of pheochromocytoma unveils a spectrum of macroscopic and microscopic features. The tumors, often yellow-tan, exhibit a zell ballen pattern under the microscope, characterized by nests of polygonal/spindle-shaped neuroendocrine chief cells with peripheral glial sustentacular cells. Immunohistochemistry further confirms their identity, with positive markers for chromogranin and synaptophysin in chief cells and S-100 antigen in sustentacular cells.

Also Read: Metabolic Syndrome- NEET SS Medicine

Diagnosis and Detection:A Symphony of Tests

Plasma Tests

• Plasma Metanephrines: High sensitivity (>99%) and low specificity.
• 24-Hour Urinary Test: Highly specific (93-95%) for pheochromocytoma.

Imaging Techniques

• MRI: A high-sensitivity modality revealing the "light bulb" sign.
• CT Scan: A quick and effective first-line test for adrenal masses.

Nuclear Medicine Imaging

• MIBG Scintigraphy: Sensitive but with limitations.
• Octreoscan: Specific for paragangliomas.
• PET/CT Scans: Advanced imaging offering high sensitivity and specificity.

Also Read: Management of Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) 

Treatment and Management: Navigating the Surgical Landscape

Preoperative Care

• Alpha-adrenergic Blockade: Phenoxybenzamine takes center stage.
• Fluid and Salt Intake: Intravascular volume expansion with isotonic fluids.

Intraoperative Management

• Anesthetic Agents: Isoflurane and enflurane lead the way.
• Blood Pressure Control: Vasodilators and short-acting beta-blockers come into play.

Surgical Intervention

• Laparoscopic Adrenalectomy: The preferred minimally invasive approach.
• Open Surgery: Considered for large tumors or local invasion.

Postoperative Care

• Vigilant monitoring for complications like hypoglycemia and hypertension.
• Surveillance with annual biochemical testing post-surgery.

Malignant Pheochromocytoma

Decoding the Malignancy

Malignant pheochromocytomas, though rare (5-10%), pose a significant challenge in diagnosis and treatment. Factors suggestive of malignancy include an increased PASS score, elevated Ki67, capsular and vascular invasion.

Treatment Modalities

• Surgical Resection: The primary choice when feasible.
• Alpha-adrenergic Blockers: Phenoxybenzamine plays a crucial role.
• 131I-MIBG Therapy: Targeted radionuclide therapy to reduce tumor size.
• DOTATOC labeled with Yttrium or Lutetium: Another avenue of targeted radionuclide therapy.
• Chemotherapy: Limited effectiveness, with some protocols involving dacarbazine, vincristine, and cyclophosphamide.

Pheochromocytoma in Pregnancy

A Delicate Balancing Act

Pheochromocytoma in pregnancy introduces a delicate balance, with potential risks for both mother and fetus. Diagnosis and management depend on the trimester of pregnancy during which the condition is detected.

First and Second Trimesters

Initiate medical management with alpha-blockers. Plan for surgical removal ideally in the second trimester.

Third Trimester

Consider gestational age and maternal-fetal status. Balance medical management until safe delivery, followed by postpartum surgical resection if near term. Emergency interventions may necessitate a cesarean section followed immediately by adrenalectomy.

In conclusion, navigating the labyrinth of Hereditary Pheochromocytoma and Paragangliomas Syndrome demands a multidisciplinary approach. From deciphering the genetic code to orchestrating surgical interventions, a collaborative effort is essential for unraveling the complexities of this rare and enigmatic syndrome. Early detection, comprehensive diagnostics, and tailored management strategies are the key instruments in this symphony of care.

Also Read: Special Considerations in Diabetes Mellitus

Hope you found this blog helpful for your NEET SS Endocrinology Preparation. For more informative and interesting posts like these, keep reading PrepLadder’s blogs.